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Cell-based myocardial repair is a 21st century approach to
an intractable problem. Because the adult heart lacks a
substantive pool of precursor, stem, or reserve cells, it is
incapable of effective cardiomyocyte regeneration after injury
or infarction. In fact, after an acute myocardial infarction, the
injured myocardium becomes a non-contracting fibrous scar,
which alters the workload of the surrounding myocardium. If
the infarct is large enough, the remaining myocardium will
ultimately deteriorate leading to congestive heart failure.
Current treatment options for acute myocardial infarction and
subsequent failure include medical management, cardiac
transplantation, mechanical circulatory left ventricular assist
devices, or other experimental attempts (artificial hearts), all
of which suffer from specific limitations. In light of the limited
efficacy and comorbidity of these current treatment options,
alternative, additional long-term therapeutic strategies are
needed. Supplying cells capable of cardiac repair is one
potential new therapeutic option.
Cell-based myocardial repair
For the treatment of cardiovascular disease states ranging
from heart attack to end-stage heart disease, we are
developing a cell transplantation technology, ‘cellular
cardiomyoplasty’ (CCM), to regenerate functioning muscle in
previously infarcted, scarred or dysfunctional myocardial
tissue after transplantation of myogenic cells. To date, many
types of cells have been transplanted into injured
myocardium, including fetal cardiomyocytes [1], autologous
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Abstract
Cell transplantation to repair or regenerate injured myocardium is a new frontier in the treatment of
cardiovascular disease. Even though it is based on many years of pre-clinical studies, much remains to
be understood about this methodology, even as it progresses to the clinic. For example, controversies
exist over the specific cells to be used, the dosages needed for tissue repair, how cells will affect the
electrical activity of the myocardium, and even whether the cells can improve myocardial function after
transplantation — all of which are briefly reviewed here. Autologous skeletal myoblasts appear to be the
most well studied and best first generation cells for cardiac repair. Yet cardiocytes and, more recently,
stem cells have been proposed as cell sources for this technology. Their advantages and limitations are
also discussed. Although cellular cardiomyoplasty (cell transplantation for cardiac repair) shows great
pre-clinical promise, its future will heavily depend on conducting carefully controlled, randomized clinical
trials with appropriate endpoints. Utilizing biologically active cells provides both an opportunity for tissue
repair and the potential for not yet understood outcomes. As with any frontier, many pioneers will
attempt to conquer it. But also as with any frontier, there are pitfalls and consequences to be considered
that may surpass those of previous endeavors. The future thus requires careful consideration and well-
designed trials rather than haste. The promise for cell transplantation is too great to be spoiled by ill-
designed attempts that forget to account for the biology of both the cells and the myocardium.
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skeletal myoblasts [2–4], smooth muscle cells [5],
immortalized myoblasts [6], syngeneic skeletal myoblasts [7],
fibroblasts [8], adult cardiac-derived cells [9], embryonic
stem cells [10], and bone marrow derived stromal [11] and
stem cells [12]. Although several of these cell types may hold
future promise as a therapeutic option, to date only skeletal
myoblasts have been used in a safety trial as a first step
toward myocardial repair [13].
Autologous skeletal myoblasts
Using skeletal myoblasts to repair injured heart is a
straightforward, but not simple, procedure. It requires
harvesting skeletal muscle, expanding cells in a laboratory,
and re-injecting cells into a patient’s heart. Using self-derived
(autologous) skeletal myoblasts, we are able to overcome the
major limitations associated with other cell-based treatments.
Most notably, we overcome the shortage of donor tissue, the
need for immunosuppression, and the ethical dilemma
associated with the use of allogeneic or embryonic cells.
Using primary cells, rather than immortalized or totipotent
stem cells, we decrease the likelihood of tumor formation
after cell transplantation [14]. Using myogenic (versus non-
myogenic) cells, we can potentially regenerate contractile
muscle in previously infarcted heart. Finally, using relatively
ischemia-resistant skeletal myoblasts rather than cardiocytes,
we can obtain higher levels of cell engraftment and survival in
infarcted regions of the heart, where cardiocytes would
probably perish [15]. Nonetheless, myoblast CCM is not
without potential limitations. For example, using autologous
cells necessitates sufficient time between injury and re-
injection to grow cells in the laboratory. Yet this waiting
period may be in line with nature’s demands in that injecting
cells too soon after an infarct seems to limit the number of
cells that survive, presumably due to the inflammatory
response that occurs after an injury.
There have been numerous reports of successful engraftment
of autologous skeletal myoblasts into injured myocardium in
multiple animal models of cardiac injury. These studies have
shown that autologous skeletal myoblasts can differentiate
and develop into striated cells within the damaged
myocardium [2].
Four promising effects of skeletal myoblast CCM have been
reported to date. The first effect was adequate survival and
engraftment of myoblasts in infarcted, necrotic, or toxin-
injured heart [2,16,17]. Survival and engraftment of
myoblasts after single or multiple injections of varying
numbers of myoblasts have also been noted [2,17]. Another
effect was improved myocardial functional performance
irrespective of the method used to assess function, in vitro
(dP/dt, force transduction) or in vivo (sonomicrometry,
echocardiography) [2,7,16,17]. Finally, myocardial
performance was augmented in all animal species studied
(rat, rabbit, dog, pig, sheep) [2,7,16–18] and more recently
in humans [13].
These results suggest that regeneration of functional muscle
after myoblast implantation could offer a valuable treatment
option for injured and failing heart. Clinical trials based on
these data have begun both in Europe and in the United
States.
Although the pre-clinical and initial clinical data appear
positive, CCM with skeletal myoblasts is not proven. Even
though it is the most well-defined technique for myocardial
regeneration, many important questions remain — questions
that will need to be answered for any CCM technique.
Probably the most important questions are those related to
cell survival, integration, differentiation, and functional effect.
For example, if CCM is to be viewed as a long-term solution
to myocardial injury, cells must be able to survive for years in
the heart. Yet the long-term fate of myoblasts is unclear.
Similarly, it is not yet clear if and how myoblasts electrically
integrate into the surrounding myocardium and what impact
integration may have on either function or rhythmicity. Finally,
there is some debate whether myoblasts improve contraction
or just prevent further deterioration of the injured heart. These
debates are being resolved with further research, and the
future for myoblast transplantation appears promising. The
understanding gained about myoblast CCM will provide a
basis for developing second and third generation cells for
cardiac repair.
Cardiocytes and stem cells
Although skeletal myoblasts appear to be the best first
generation cell for use in myocardial repair, the intriguing
question remaining is: what cell type will ultimately be best
for myocardial repair? Cardiocytes might seem the ideal
target cell at first glance. Yet several major obstacles remain
to the use of these cells in vivo. First, for cardiocytes to be
used for cell transplantation they must be readily available as
a cell source. Given their inability to replicate to a significant
degree in vitro or in vivo, this remains unlikely at present.
Second, for cardiocytes to survive in infarcted heart, they will
require a vascular supply far greater than that required for
myoblast survival and one unlikely to easily be obtained in
infarct. Finally, if cardiocytes are ever to contribute to
myocardial function, they must align in a manner that allows
them to electrically and mechanically couple to the remainder
of the myocardium. At present, little or no data exist
demonstrating this is possible.
Bone marrow derived stem cells have recently received
attention as an ideal target for cardiac repair [11,12,19]. By
their very nature, these multipotent stem cells respond to
their microenvironment and develop a corresponding
phenotype. This would suggest that, in normal myocardium,
stem cells could become cardiocytes and integrate with
surrounding host tissue. Data from several laboratories
suggest this is feasible, although it appears to be a rare event
[20]. But the data further suggest, as shown by Wang et al
[11], that when injected into injured or infarcted heart stemCurrent Controlled Trials in Cardiovascular Medicine    October 2001 Vol 2 No 5 Taylor
cells will develop characteristics of scar. Understanding this
phenomenon and beginning to control it is an active area of
investigation that must be better understood before stem
cells per se will be a viable target for myocardial repair.
More recent data suggest that lineage negative (Lin–)
c-kitPOS subpopulations of stem cells can be derived and
supplied in numbers sufficient to repopulate infarcted regions
of myocardium with cardiocytes and vascular structures [12].
Although this is an extremely exciting development, these
data have only been obtained in the mouse heart, where the
infarct size is exceedingly small. Furthermore, the functional
impact of these cells has not been rigorously evaluated.
Translating these initial results into larger, more
physiologically relevant, models of human cardiac disease is
the critical next step in evaluating stem cell contribution to
cardiac repair. Taken together, these data illustrate the
potential of utilizing a multipotent stem cell for cardiac repair.
Unfortunately, although the idea of finding one cell that can
repair injured heart is intriguing, our understanding of stem
cell biology is not presently sufficient to allow us to do so.
Challenges to CCM
Several challenges remain if we are to successfully repair
infarcted or failing myocardium with any type of cell. The
majority of these challenges seem straightforward, but they
are complicated by the extreme heterogeneity of
cardiovascular disease. For example, the criteria for
reproducible engraftment of large numbers of cells may be
very different in the early post-myocardial infarction patient
versus the patient with end-stage cardiac dysfunction.
Similarly, the method of delivering cells (surgical versus
endovascular), the concentration of cells delivered, and a
host of other criteria ranging from age to co-existing disease
states have to be considered as cell transplantation emerges
into clinical trials. Finally, the most significant challenges to
cell repair of injured myocardium evolve from our attempts to
achieve more than simply halting the progression of
cardiovascular deterioration. Pre-clinical data suggest that
growth factors, fibroblasts or any number of cells may be
able to slow or actually improve diastolic dysfunction [8,21].
Yet, if we wish to improve the contractility of the infarcted
heart, we must implant cells that can electrically integrate into
the heart and survive for extended periods of time. This may
involve more than simple cell engraftment, and may ultimately
depend on engineered grafts in which we can guarantee
nutrient delivery and blood supply in an infarcted region of
tissue, and protect the surrounding myocardium from
mechanical remodeling and decompensation secondary to
these grafts. Although this is not at the forefront of
myocardial repair today, it is an area that cannot be ignored.
Conclusion
Cell transplantation for myocardial repair has arrived.
Carefully evaluating this new modality provides an
opportunity to define a new era in the treatment of
cardiovascular disease. Combining genomics, tissue
engineering, and advanced imaging methods to define the
best cell type(s), to understand the mechanism(s) of cell
engraftment on function, to promote graft longevity, and to
improve electromechanical graft integration is the next pre-
clinical frontier. Designing clinical trials that allow us to
adequately evaluate the safety and efficacy of cell
transplantation in the absence of complicating adjunctive
therapies is crucial [22]. Doing it improperly could relegate
the field to failure before its potential is realized.
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